Navigation Links
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Date:11/1/2007

ill be able to move this drug candidate into the clinic later this year, given its great therapeutic potential, not only in cancer, but also in severe eye diseases that are the major causes of blindness."

Svein Mathisen, CEO of BioInvent, added: "The data presented in this seminal paper more fully explains the tumour inhibition findings obtained in our preclinical program to date. Through this experimental work, the development path for the collaboration partners has been clarified and the potential for TB-403, as a novel treatment for cancer, has been emphasized. I feel confident in my belief that TB-403 will secure a prominent place in the oncology armoury."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... 2011 Myriant Technologies, Inc. (Myriant), a ... bio-based chemicals, announced today the closing of ... PTT Chemical Group (PTT Chemical), Thailand,s largest ... Myriant will utilize the investment ...
... new scientific discovery could have profound implications for nanoelectronic ... Bohr Institute, University of Copenhagen, in collaboration with Japanese ... graphite exhibit a unique interaction between their motion and ... discovery paves the way for unprecedented control over the ...
... NewLink Genetics Corporation today announced that additional data from ... HyperAcute® Pancreas cancer immunotherapy will be presented during a ... 2011 Gastrointestinal Cancers Symposium in San Francisco, California. A ... Title: Effect of the addition of algenpantucel-L immunotherapy to ...
Cached Biology Technology:Myriant Technologies, Inc. Announces US$60 Million Strategic Equity Investment From PTT Chemical Group 2Myriant Technologies, Inc. Announces US$60 Million Strategic Equity Investment From PTT Chemical Group 3Curved carbon for electronics of the future 2NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 2NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 3NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium 4
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... hot weather, such as last year,s heat wave that gripped ... September? Scientists studying the subtle effects of heat waves ... big difference. Based on more than 25 years of ... Ecological Research (LTER) site in Kansas--one of 26 such NSF ...
... assistant professor of biochemistry at Virginia Tech, has ... administered by the Ministry of Science and Technology ... is "a significant contribution to the diagnosis and ... a release distributed my MICIT. Sobrado, an ...
... community a new way of figuring out exactly how one ... University of Central Florida Engineering Assistant Professor Shaojie Zhang ... the subunits that make up RNA (ribonucleic acid). ... with DNA and proteins. Knowing how all three building ...
Cached Biology News:Time of year important in projections of climate change effects on ecosystems 2Contributions to diagnosis, treatment of tropical diseases recognized 2
... be able to handle larger sample volumes, automate ... as interface with telemetry systems. The AccuSampler ... dogs, pigs, and primates. The system may ... the computer can be located outside the animal ...
... a regulated environment, Pipette Tracker Pro ... that automates gravimetric pipette calibration and ... meets todays regulatory compliance requirements. Pipette ... that includes a full security implementation, ...
... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
... which no antibody exists? Having difficulty generating antibodies ... variety of pharmaceutical, biotech and academic researchers and ... and expertise in antibody generation to work for ... development technology , High affinity and high specificity ...
Biology Products: